Jay Overholser

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Despite the promise of targeted therapies, there remains an urgent need for effective treatment for esophageal cancer (EC) and triple-negative breast cancer (TNBC). Current FDA-approved drugs have significant problems of toxicity, safety, selectivity, efficacy and development of resistance. In this manuscript, we demonstrate that rationally designed peptide(More)
  • 1